Fig. 5.

AKS-452 IgG titers against SARS-Cov-2 viral variants. Serum samples were obtained at Day 0, 28, 56, 90, and 180 from the initial vaccine dose from Cohorts 1 and 2 and assessed for IgG binding titers against SP/RBD from different SARS-CoV-2 variants via ELISA and presented per subject with mean ± SEM per cohort. For comparison, the dotted reference lines denote the highest and lowest mean titers from the Original Washington WT strain (see Fig. 2). HCS from unvaccinated individuals during the first wave of SARS-CoV-2 infection (i.e., Original Washington strain) was used as a comparator to samples from vaccinated subjects. For each viral variant, statistical comparisons between days “within a cohort” and “between cohorts” were performed using a model entailing “cohort” and “day” values as fixed effects and a “random subject effect” using log-transformed values in which p values were adjusted for multiplicity (Tukey-Kramer). *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001; ^#, p ≤ 0.0001 vs. Cohort 1 days 28, 56, or 90.